

# Other Support

**SCHULZ, Paul**

## **ACTIVE**

AGT004414 03/13/2021 – 12/31/2024 0.15 CM

American College of Radiology (ACR) \$125,000 Total Cost

New IDEAS: Imaging Dementia - Evidence for Amyloid Scanning Study: A Study to Improve Precision in Amyloid PET Coverage and Patient Care

Goal: The goal is to improve precision in Amyloid PET Coverage and Patient Care for dementia participants and provide ACR with all web-based CRFs applicable to the individual study participant cases.

Role: PI

R01 AG66749-01A1 (Jiang) 04/01/2020 – 03/31/2025 1.20 CM

NIH/NIA \$499,914.00 Total Cost

Finding combinatorial drug repositioning therapy for Alzheimer's disease and related dementias

GOAL: The goal of this project is to identify novel drug combination therapies for AD/ADRD prevention and treatment using advanced informatics methods.

Role: Co-Investigator

R01 AG66749-01A1 (Jiang) 07/01/2020 – 06/30/2021 1.20 CM

NIH/NIA \$250,000 Co-vid Supplement

Finding combinatorial drug repositioning therapy for Alzheimer's disease and related dementias- Co-vid Supplement

GOAL: There are many large medical databases that contain information about medications that were given for one reason that could “accidentally” reduce the risk of developing AD or change its rate of progression. It is difficult to identify them because the number of variables in such a database is very large; however, here we will use advanced informatic methods to examine several large databases to reveal novel drug combination therapies that may be helpful for treating Covid-19.

Role: Co-Investigator

R01AG067498-01 (Du) 04/01/2020 – 03/31/2025 0.60 CM

NIH/NIA \$1,558,333 total costs

The Risk of Developing Alzheimer's Disease and Related Dementias Associated with Hypertension, Diabetes, and Drug Therapies for Cancer: Up to 30-year Follow-up for Older Medicare Beneficiaries

Goal: Use a large Medicare database to reveal medications for hypertension, diabetes, and cancer that may reduce the risk of developing Alzheimer's disease that can then be repurposed for preventing or treating AD.

Role: Co-Investigator

W81XWH-17-1-0559 (Soto) 09/15/2017 - 6/30/2022 0.60 CM

Department of Defense \$769,998.00 Total Costs

Detection of amyloid-beta and tau misfolded oligomers in biological fluids of TBI and AD patients

This goal of this grant from the Department of Defense is to develop and test the protein misfolding cyclic amplification (PMCA) technology for high sensitivity detection of misfolded amyloid and tau oligomers, implicated in Alzheimer's disease, in patients with traumatic brain injury.

Role: Co-Investigator

R42 AG05833 (Vollrath/Soto, MPI) 04/01/2018 – 08/31/2021 0.60 CM

NIH \$388,759.00 Total Costs

Highly selective detection of tau oligomers in biological fluids for the diagnosis of Alzheimer's Disease  
The purpose of the study is to develop and test the PMCA technology for high sensitivity detection of misfolded tau oligomers implicated in Alzheimer's disease.

Role: Co-Investigator

RF1 AG055053 (Soto) 09/01/2019-08/31/2024 1.20 CM  
NIH/NIA \$2,897,592 Total Costs

Comprehensive diagnosis of Alzheimer's disease by detection of misfolded oligomers in biological fluids  
The goal of this study is to comprehensively analyze misfolded oligomers in biologic fluids as a way to more accurately diagnose AD.

Role: Co-Investigator

R01 AG061069 (Soto/Arduino, MPI) 10/01/2018 – 09/30/2023 0.60 CM  
NIH/NIA \$1,151,389.00 Total Costs

Misfolded protein aggregates in HIV infection

The goal of this project is to comprehensively study the presence of misfolded protein aggregates in the brain and biological fluids of HIV-infected patients.

Role: Co-Investigator

R21 NS114884-01 (Shahnawaz) 04/15/2020- 03/31/2022 0.60 CM  
NIH/NINDS \$426,000 Total Costs

Development of Blood Based Diagnosis of Parkinson's Disease

The major research goal is to extend the applicability of PMCA technology to detect small amounts of  $\alpha$ Syn oligomers present in blood plasma so a cheap, noninvasive and reliable diagnostic test could be developed.

Role: Co-Investigator

Schulz 01/15/2019 – 01/14/2022 0.15 CM  
Roche Pharmaceuticals Corporation \$2,036,864.00 Total Costs

A Phase III, Multicenter, randomized, double-blind, placebo-controlled, parallel-group, Efficacy, and Safety Study of Gantenerumab in Patients with Early (Prodromal to Mild) Alzheimer's disease"

The goal of this trial is to test the safety and efficacy of this anti-amyloid antibody, which is injected monthly, for delaying the progression of Alzheimer disease.

Role: Site PI

No Identifying No. (Soares) 09/27/2013 – 12/31/2030 0.15 CM  
Dunn Foundation \$870,150.00 Total Costs

Deep Brain Stimulation for Refractory Major Depressive Disorder"

The goal of this study is to test the safety and efficacy of deep brain stimulation, targeting the median forebrain bundle, in patients with refractory major depressive disorder.

Role: Co-Investigator

3R15NR018050-01A1S1 (Ahn) 07/01/2020 – 06/30/2021 0.60 CM  
NIH \$160,143.00 Total Cost

Home-based Transcranial Direct Current Stimulation for Pain Management in Persons with Alzheimer's Disease: Supplement

Goal: The goal is to improve pain management using home-based non-pharmacological approaches.

Role: Co-Investigator

1R01AG062690-01 Sub-in (Green, Schulz) 06/15/2019- 03/31/2024 0.60 CM  
NIH via Rice University \$276,423.00 total award to UTHealth

Individual Differences in Dementia Spousal Caregiver Burden: A Biobehavioral Approach

Goal: to understand the stressors that caregivers have in supporting their loved ones with Alzheimer.

Role: Co-Investigator

No Identifying No. (Schulz) 06/26/2020 06/26/2023 0.15 CM  
Eli Lilly & Company \$1,083,209 Total Cost  
Assessment and Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease  
Goal: The goal is this study is to test the safety and efficacy of the anti-amyloid antibody, Donanemab, for treating Alzheimer's disease.  
Role: Site PI

No Identifying No. (Schulz) 04/01/2021 – 03/31/2026 0.15 CM  
AbbVie Pharmaceuticals \$2,583,023 Total Cost  
"M15-570: A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimer's Disease. Extension study."  
Goal: The goal of this trial is to test the safety and efficacy of a monthly I.V. infused tau protein antibody for delaying the progression of Alzheimer disease.  
Role (PI)

1R21 AG68994-01 (Cui) 07/01/2020 – 06/30/2022 1.20 CM  
NIH/NIA \$422,502.00 Total Cost  
An Interface Ontology for Alzheimer's Disease Research  
The main goal of this project is to develop a novel ontology and data exploration interface for managing, querying, and exploring research data related to Alzheimer's disease (AD). P002190  
Role: Co-Investigator

1R01AG059321-01A1 (Soto/Morales, MPI) 07/01/2020 – 06/30/2025 0.60 CM  
NIH/NIA \$ 3,639,505 Total Cost  
Role of circulating Abeta seeds and peripheral tissue damage in Alzheimer's disease pathogenesis.  
The long term goal of this project is to understand how modifications in peripheral structures (tissues and blood) contribute to the progression of pathological changes associated to AD and use this knowledge to develop novel strategies for treatment and diagnosis.  
Role: Co-Investigator